Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.44 |
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.43 |
| ▸ | TOP2B known ✓ | Q02880 | 1/20 | 0.43 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.43 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.39 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17965485 | 0.98 | CYP1A2 (0.74) | CYP1A2CYP2D6HTR1DHTR1BTOP2A | |
| SCHEMBL13990186 | 0.84 | CYP1A2 (1.00) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| SCHEMBL11190221 | 0.83 | CYP1A2 (0.74) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| SCHEMBL10691316 | 0.81 | CYP1A2 (0.82) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| SCHEMBL11135471 | 0.80 | CYP1A2 (0.71) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| SCHEMBL23121057 | 0.80 | CYP1A2 (0.70) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| SCHEMBL10690989 | 0.78 | CYP1A2 (0.67) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| SCHEMBL2514598 | 0.75 | CYP1A2 (0.63) | CYP1A2CYP2D6HTR1DTAAR1TSHR | |
| SCHEMBL28160686 | 0.74 | CYP1A2 (0.58) | CYP1A2CYP2D6HTR1DHTR1BDRD4 | |
| Hydrochloric Acid SCHEMBL7346644 | 0.74 | HTR1D (0.52) | CYP1A2CYP2D6HTR1DHTR1BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023133143-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| US-9492525-B2 | Human respiratory syncytial virus vaccine | NANOBIO CORPORATION (US) | 2016-11-15 | — | — | US | claimed |
| EP-2729169-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | Nanobio Corporation (US) | 2014-05-14 | — | — | EP | claimed |
| EP-2545937-A1 | Nanoemulsion vaccines | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-16 | — | — | EP | claimed |
| WO-2013006797-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION (US) | 2013-01-10 | — | — | WO | claimed |
| US-20130011443-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION | 2013-01-10 | — | — | US | claimed |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2012-11-01 | — | — | US | claimed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| US-20090304799-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION | 2009-12-10 | — | — | US | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| WO-2009132342-A1 | NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009132343-A1 | NANOEMULSIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090143476-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| US-20090143477-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| US-6559189-B2 | For decontaminating areas, samples, solutions, and foodstuffs colonized or infected by pathogens and microorganisms | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-05-06 | — | — | US | claimed |
| US-20020045667-A1 | Non-toxic antimicrobial compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | HTR1D 4779/4885HTR1B 4409/4885TOP2A 921/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | HTR1D 4701/4885HTR1B 4592/4885TOP2A 1902/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | HTR1D 4789/4885HTR1B 4478/4885TOP2A 720/4885 |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | HTR1D 4701/4885HTR1B 4592/4885TOP2A 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.